Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WBI-1001 in Atopic Dermatitis
NCT00837551Phase 2Completed
- Sponsor
- Welichem Biotech
- Start
- Mar 2008
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tapinarof in atopic dermatitis (AD) (3 arms), sponsored by Welichem Biotech. Primary endpoint: Skin lesion condition at 35 days. Started Mar 2008; status: completed.
02
Drugs
tapinarof
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT00837551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00837551.